An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method

Alan A Martin,1 Daniel Parks2 1Department of Value Evidence Analytics, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Department of Value Evidence Analytics, GlaxoSmithKline, Collegeville, PA, USA Abstract: No head-to-head comparisons exist between once-weekly (QW) glucagon-like peptide-1 receptor agoni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin AA, Parks D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Albiglutide exenatide QW GLP-1 RA Bucher method Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/e1c6761f3e404fedb576f634058e8b92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1c6761f3e404fedb576f634058e8b92
record_format	dspace
spelling	oai:doaj.org-article:e1c6761f3e404fedb576f634058e8b922021-12-02T01:28:18ZAn indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method1178-7007https://doaj.org/article/e1c6761f3e404fedb576f634058e8b922016-05-01T00:00:00Zhttps://www.dovepress.com/an-indirect-comparison-of-hba1c-treatment-effect-with-albiglutide-and--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Alan A Martin,1 Daniel Parks2 1Department of Value Evidence Analytics, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Department of Value Evidence Analytics, GlaxoSmithKline, Collegeville, PA, USA Abstract: No head-to-head comparisons exist between once-weekly (QW) glucagon-like peptide-1 receptor agonists; accordingly, this indirect comparison was conducted to evaluate the comparative efficacy of QW albiglutide vs QW exenatide. Following a systematic literature search, it was determined that HARMONY 7 and DURATION 6, Phase III trials for albiglutide and exenatide, respectively, were similar in study design and baseline characteristics and included a common comparator arm, making them suitable for an indirect comparison using the Bucher method. The primary endpoint of change from baseline in glycated hemoglobin (HbA1c) with albiglutide 50 mg QW and exenatide 2.0 mg QW was compared and tested for noninferiority. The indirect comparison showed a treatment difference of 0.0% (95% confidence interval: -0.189% to 0.189%) in mean change in HbA1c from baseline, and albiglutide 50 mg was noninferior to exenatide 2.0 mg QW at the noninferiority margin of 0.3%. In the absence of a head-to-head trial, these results can be used in pharmacoeconomic analysis and to inform health technology assessment and clinical decision making. Keywords: albiglutide, exenatide 2.0 mg QW GLP-1 RA, Bucher methodMartin AAParks DDove Medical PressarticleAlbiglutideexenatide QWGLP-1 RABucher methodSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 163-168 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Albiglutide exenatide QW GLP-1 RA Bucher method Specialties of internal medicine RC581-951
spellingShingle	Albiglutide exenatide QW GLP-1 RA Bucher method Specialties of internal medicine RC581-951 Martin AA Parks D An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
description	Alan A Martin,1 Daniel Parks2 1Department of Value Evidence Analytics, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Department of Value Evidence Analytics, GlaxoSmithKline, Collegeville, PA, USA Abstract: No head-to-head comparisons exist between once-weekly (QW) glucagon-like peptide-1 receptor agonists; accordingly, this indirect comparison was conducted to evaluate the comparative efficacy of QW albiglutide vs QW exenatide. Following a systematic literature search, it was determined that HARMONY 7 and DURATION 6, Phase III trials for albiglutide and exenatide, respectively, were similar in study design and baseline characteristics and included a common comparator arm, making them suitable for an indirect comparison using the Bucher method. The primary endpoint of change from baseline in glycated hemoglobin (HbA1c) with albiglutide 50 mg QW and exenatide 2.0 mg QW was compared and tested for noninferiority. The indirect comparison showed a treatment difference of 0.0% (95% confidence interval: -0.189% to 0.189%) in mean change in HbA1c from baseline, and albiglutide 50 mg was noninferior to exenatide 2.0 mg QW at the noninferiority margin of 0.3%. In the absence of a head-to-head trial, these results can be used in pharmacoeconomic analysis and to inform health technology assessment and clinical decision making. Keywords: albiglutide, exenatide 2.0 mg QW GLP-1 RA, Bucher method
format	article
author	Martin AA Parks D
author_facet	Martin AA Parks D
author_sort	Martin AA
title	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
title_short	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
title_full	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
title_fullStr	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
title_full_unstemmed	An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
title_sort	indirect comparison of hba1c treatment effect with albiglutide and exenatide 2.0 mg qw using the bucher method
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/e1c6761f3e404fedb576f634058e8b92
work_keys_str_mv	AT martinaa anindirectcomparisonofhba1ctreatmenteffectwithalbiglutideandexenatide20mgqwusingthebuchermethod AT parksd anindirectcomparisonofhba1ctreatmenteffectwithalbiglutideandexenatide20mgqwusingthebuchermethod AT martinaa indirectcomparisonofhba1ctreatmenteffectwithalbiglutideandexenatide20mgqwusingthebuchermethod AT parksd indirectcomparisonofhba1ctreatmenteffectwithalbiglutideandexenatide20mgqwusingthebuchermethod
_version_	1718403106399584256

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method

Ejemplares similares